NCT00979134 - Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2009

Primary Completion Date

February 12, 2014

Study Completion Date

March 5, 2015

Conditions

CancerAdvanced Solid Malignancies

Interventions

DRUG

AZD4547

Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily

DRUG

AZD4547

Patients start at a dose of 80 mg twice daily, with no washout

DRUG

AZD4547

Single dose is followed by washout 5-10 days before multiple dose

Trial Locations (29)

10021

Research Site, New York

19111

Research Site, Philadelphia

20089

Research Site, Rozzano

28222

Research Site, Majadahonda

37232

Research Site, Nashville

46010

Research Site, Valencia

46026

Research Site, Valencia

48201

Research Site, Detroit

50924

Research Site, Cologne

60488

Research Site, Frankfurt

69495

Research Site, Pierre-Bénite

77030

Research Site, Houston

79106

Research Site, Freiburg im Breisgau

80045

Research Site, Aurora

80131

Research Site, Napoli

94305

Research Site, Stanford

94805

Research Site, Villejuif

06520

Research Site, New Haven

1066 CX

Research Site, Amsterdam

3015 CE

Research Site, Rotterdam

06008

Research Site, Badajoz

B9 5SS

Research Site, Birmingham

EH4 2XU

Research Site, Edinburgh

G12 0YN

Research Site, Glasgow

W12 0NN

Research Site, London

W1G 6AD

Research Site, London

M20 4BX

Research Site, Manchester

NE7 7DN

Research Site, Newcastle upon Tyne

WV10 0QP

Research Site, Wolverhampton